The loss of vaginal collagen can lead to diminished sexual sensation.
During the consultation, our US Board Certified and Harvard-trained doctor, Dr. Sylvia Ramirez, will discuss about the concern and she will also explain in full details the benefits of Geneveve by Viveve, a single non-surgical treatment that renews collagen and improves sexual sensation.
Just like skin, vaginal tissue is made up of collagen fibers. During vaginal childbirth or sexual activity, these tissues can overstretch, damaging the collagen and creating a feeling of looseness, especially around the vaginal opening.
Women who experience this loss of tightness may also notice a decreased feeling of sensation and sexual satisfaction during intercourse. These changes can affect a woman’s over all sexual health, her relationship, her confidence and her self-love.
Geneveve by Viveve safely treats the feeling of looseness by using a patented radiofrequency (RF) technology to tighten the tissues around the vaginal opening. Unlike surgical vaginal reconstruction procedures, the Geneveve System can tighten vaginal tissue without incisions or tissue ablations.
The Geneveve Treatment is not cosmetic, instead, it works at the cellular level to rebuild and restore collagen and as a result can increase feelings of vaginal tightness and improve sexual satisfaction. The treatment can be completed in 30 minutes, is performed without anesthesia, and results in little-to-no downtime.
Disclaimer: Results may vary according to individual.
Geneveve by Viveve is a non-surgical, cryogen-cooled, monopolar radio frequency (CMRF) therapy that provides a novel, outpatient modality to effectively and noninvasively treat vaginal laxity.
Geneveve delivers dual-mode monopolar RF with cryogen cooling to protect the surface while enabling heat to reach the deeper underlying tissue layers. This dual-mode (heating and cooling) therapy coupled with surface cooling activates fibroblasts to produce new collagen and stimulates remodeling of vaginal tissue without evidence of fibrosis or underlying scarring. Moreover, without cooling, there is a possibility of thermal injury in the vaginal tissue.
A recent clinical trial* was conducted with 174 women from 9 sites in 4 countries (Canada, Italy, Spain, Japan) was done to evaluate the changes in the Female Sexual Function Index (FSFI) of the subjects who received Geneveve therapy for the treatment of vaginal laxity. This is the first, and only, randomized, placebo controlled trial with a measurable comparison of energy-based therapy for the treatment of vaginal laxity.
The clinical trial showed that a single, non-ablative (non-wounding) Geneveve treatment improves overall sexual function and is associated with statistically significant and sustainable improvements on the individual FSFI (Female Sexual Function Index) domains of sexual sensation in women with vaginal laxity and baseline sexual dysfunction.
*TREATMENT OF THE VAGINAL INTROITUS TO EVALUATE EFFECTIVENESS: Bruce Allan MD1, Debbie Wilkerson PhD2, Michael L Krychman MD3. 2016